Skip to content
MRD Watch

Wednesday, November 18, 2026

Subscribe
Sponsor this briefing. One site and newsletter slot, $250/week.

Briefing

Results of the c-TRAK TN trial: a clinical trial utilising ctDNA mutation tracking to detect molecular residual disease and trigger intervention in patients with moderate- and high-risk early-stage triple-negative breast cancer.

The phase 2 c-TRAK TN trial used prospective digital-PCR ctDNA surveillance after treatment for early triple-negative breast cancer and tested pembrolizumab in people who became ctDNA-positive.

Annals of OncologyPubMed 36423745DOI 10.1016/j.annonc.2022.11.005